Myofrastand

21/03/2026

At the Global Health Innovation Summit - 2026, Dr. Pessanha emphasized that APOE4 should be understood as a genetic susceptibility factor rather than a deterministic gene. Carrying APOE4 increases the probability of developing Alzheimer’s disease, but it does not define an individual’s outcome.

Importantly, she highlighted the distinction between late-onset and early-onset Alzheimer’s disease. While late-onset Alzheimer’s is influenced by risk genes such as APOE4, early-onset familial Alzheimer’s is typically driven by rare, deterministic mutations in genes such as APP, PSEN1, and PSEN2, which are strongly associated with disease development at a younger age.

This perspective reinforces the importance of prevention and personalized approaches, including lifestyle interventions such as cardiovascular health, nutrition, and physical activity. It also underscores that Alzheimer’s disease is not a uniform condition, but a complex spectrum with diverse biological mechanisms and clinical trajectories.

20/03/2026

20/03/2026

At the Global Health Innovation Summit- 2026, Dr. Bishopric explored the dual nature of the APOE ε4 variant. While known today as a risk factor for Alzheimer’s, it was originally a survival tool—providing immune resistance to infectious agents in tropical environments like Brazil.

This "survival game" is written in the Brazilian genome (Nunes et al., 2025):
🔹 Paternal Lineage: ~71% European
🔹 Maternal Lineage (mtDNA): ~42% African | ~35% Indigenous

This data reflects a complex history and highlights a critical gap: nearly 9 million genetic variants in Brazil remain unrecorded in global databases. To truly understand Alzheimer’s for everyone, we must prioritize genomic equity and include neglected African and Indigenous lineages.

Innovation thrives when science is inclusive. 🔬🌎

No nosso Summit sobre Saúde Global - 2026, onde discutimos sobre Alzheimer, a Dr. Bishopric explorou a natureza ambivalente da variante APOE ε4. Embora hoje seja conhecida como um fator de risco para o Alzheimer, originalmente foi uma ferramenta de sobrevivência — proporcionando resistência imunológica a agentes infecciosos em ambientes tropicais como o Brasil.

Esse “jogo de sobrevivência” está escrito no genoma brasileiro (Nunes et al., 2025):

🔹 Linhagem paterna: ~71% europeia
🔹 Linhagem materna (mtDNA): ~42% africana | ~35% indígena

Esses dados refletem uma história complexa e destacam uma lacuna crítica que ainda existe: quase 9 milhões de variantes genéticas no Brasil ainda não estão registradas em bancos de dados globais. Para compreender verdadeiramente o Alzheimer, e outras doenças, para TODOS, precisamos priorizar a equidade genômica e incluir linhagens africanas e indígenas que não estão incluídas naqueles bancos de dados.

A inovação prospera quando a ciência também é inclusiva. 🔬🌎

09/03/2026

09/03/2026

It was a profound honor to organize this The Global Health Innovation Summit, 2026 in collaboration with Bergen New Bridge Medical Center Foundation. This gathering brought together physicians and scientists to explore the latest clinical and scientific advancements in Alzheimer’s disease and dementia. 🧠✨

Our mission was clear: to bridge the gap between complex research and our community by providing credible, science-based information grounded in published data and logical analysis. 🔬

A Heartfelt Thank You to Our Collaborators!
This event would not have been possible without the support of an incredible team:

Partnership: My deepest gratitude to Bergen New Bridge Medical Center and their visionary CEO, Mrs. Deborah Visconi, and her entire team for their unwavering support in making this summit a reality.

Dedication: A special thank you to Dr. Nanette Bishopric and Dr. Lukshmi Puttanniah for adjusting their demanding schedules to support this initiative. Your commitment to our community and caregivers is truly inspiring.

Commitment: Thank you, Dr. Paula Waziry, for traveling from Florida to enrich our dialogue with your vital expertise.

Innovation: Mrs. Ilham Atir, thank you for your invaluable contributions regarding the novel, FDA-cleared Alzheimer’s biomarker tests now available at New Bridge Medical Center.

The Future: Dr. Filipe Litaiff, your insights into the role of Artificial Intelligence in early detection highlight the incredible promise of technology in clinical care. 🤖

What’s Next?
Throughout this week, I will be sharing highlights and key insights from our discussions. Whether you are a fellow scientist or a member of the broader community, I invite you to follow along as we dive deeper into the data and stories that defined this special day.

Thank you to everyone who attended and contributed. Together, we are advancing the conversation on public health and cognitive care.

HealthcareLeadership NewBridgeMedical

04/03/2026

💙 Understanding Alzheimer’s: Science, Support and Community has officially begun!

A powerful gathering dedicated to advancing research, collaboration and innovation in Alzheimer’s care and prevention.

03/03/2026

Tomorrow we come together for Understanding Alzheimer’s: Science, Support and Community.

A day dedicated to advancing research, sharing knowledge, and strengthening our community.

From AI and neuroimaging to cardiovascular health, psychology, and the gut-brain connection, this program reflects the power of multidisciplinary collaboration in shaping the future of Alzheimer’s care.

5 sessions. Big conversations. Real impact.

Join us at the Auditorium of Bergen New Bridge Medical Center!

🗓️ When: March 4
⏰ Time: 9:00 AM - 1:00 PM
📍 Where: 230 East Ridgewood Ave, Paramus, New Jersey

01/03/2026

Filipe Litaiff, PhD, Professor and Founder, Federal Institute of Rio de Janeiro, CEO of Sunyata Consulting, will be leading our fifth and last panel.

In Session 5, Dr. Litaiff will explore how artificial intelligence and advanced neuroimaging are reshaping the way we diagnose, predict, and care for patients with Alzheimer’s and dementia. From earlier detection to smarter clinical decisions, technology is opening new possibilities beyond traditional medicine.

Join us in New Jersey for “Understanding Alzheimer’s: Science, Support and Community”, a summit bringing together five experts to share insights, research and real-world perspectives on brain health.

Seats are limited, and tickets are available at the link below:

https://wl.donorperfect.net/weblink/weblink.aspx?name=E353359&id=90

01/03/2026

The gut and the brain are more connected than we once imagined.

Dr. Waziry, PhD, Medical Science Liaison, Virology, Myofrastand, Inc., will address the surprising influence of the gut on the brain in Alzheimer’s and related dementias.

In this session, Dr. Waziry dives into the powerful link between the gut-brain axis and Alzheimer’s disease, exploring how microbial byproducts may fuel neuroinflammation and cognitive decline.

Join us in New Jersey for “Understanding Alzheimer’s: Science, Support and Community”, a summit bringing together five experts to share insights, research and real-world perspectives on brain health.

Seats are limited, and tickets are available at the link below:

https://wl.donorperfect.net/weblink/weblink.aspx?name=E353359&id=90